Literature DB >> 23708172

Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results.

Alan H B Wu1, Frank Wians, Allan Jaffe.   

Abstract

BACKGROUND: Galectin-3 and soluble ST2 (sST2) are novel serum biomarkers of chronic heart failure. METHODS AND
RESULTS: The biological variability of galectin-3 and sST2 was measured from a cohort of 17 healthy subjects where blood was taken once every 2 weeks for 8 weeks (n = 4 samples) and from 12 subjects where blood was taken hourly (for galectin-3 only). The analytical, intraindividual, and interindividual variation were measured for galectin-3 (BG Medicine, Waltham, MA) and sST2 (Critical Diagnostics, San Diego, CA). From these measurements, the reference change (RCV) and index of individuality was 39% (hourly) and 61% (weekly) and 1.0 (hourly and weekly) for galectin-3. Corresponding RCV and index of individuality values for sST2 were 30% and 0.25.
CONCLUSION: The RCV result for sST2 was lower than the corresponding results for galectin-3, B-type natriuretic peptide, and N-terminal pro-B-type natriuretic peptide. These data suggest that sST2 may be more useful for monitoring long-term heart failure, and galectin-3 may be more useful for the diagnosis of heart failure remodeling.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23708172     DOI: 10.1016/j.ahj.2013.02.029

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  29 in total

Review 1.  Biological and analytical variation of clinical biomarker testing: implications for biomarker-guided therapy.

Authors:  Alan H B Wu
Journal:  Curr Heart Fail Rep       Date:  2013-12

2.  Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes.

Authors:  Anahita Ghorbani; Vijeta Bhambhani; Robert H Christenson; Wouter C Meijers; Rudolf A de Boer; Daniel Levy; Martin G Larson; Jennifer E Ho
Journal:  J Am Coll Cardiol       Date:  2018-12-25       Impact factor: 24.094

3.  Serial galectin-3 and future cardiovascular disease in the general population.

Authors:  A Rogier van der Velde; Wouter C Meijers; Jennifer E Ho; Frank P Brouwers; Michiel Rienstra; Stephan J L Bakker; Anneke C Muller Kobold; Dirk J van Veldhuisen; Wiek H van Gilst; Pim van der Harst; Rudolf A de Boer
Journal:  Heart       Date:  2016-04-15       Impact factor: 5.994

4.  Evaluation of new and old biomarkers in dogs with degenerative mitral valve disease.

Authors:  Stephanie Klein; Ingo Nolte; José Luis Granados-Soler; Philipp Lietz; Maximiliane Sehn; Jonathan Friedemann Raue; Karl Rohn; Eva-Maria Packeiser; Jan-Peter Bach
Journal:  BMC Vet Res       Date:  2022-07-02       Impact factor: 2.792

Review 5.  The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers.

Authors:  George Karayannis; Filippos Triposkiadis; John Skoularigis; Panagiotis Georgoulias; Javed Butler; Gregory Giamouzis
Journal:  Curr Heart Fail Rep       Date:  2013-12

6.  Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure.

Authors:  Dong-Hui Huang; Hao Sun; Jing-Pu Shi
Journal:  Chin Med J (Engl)       Date:  2016-03-05       Impact factor: 2.628

Review 7.  Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure.

Authors:  Humberto Villacorta; Alan S Maisel
Journal:  Arq Bras Cardiol       Date:  2016-01-15       Impact factor: 2.000

8.  Can Natriuretic Peptides be Used to Guide Therapy?

Authors:  Antoni Bayes-Genis; Josep Lupón; Allan S Jaffe
Journal:  EJIFCC       Date:  2016-08-01

9.  Soluble ST2 and Galectin-3: What We Know and Don't Know Analytically.

Authors:  Thomas Mueller; Benjamin Dieplinger
Journal:  EJIFCC       Date:  2016-08-01

10.  Soluble ST2 and mixed venous oxygen saturation for prediction of mortality in patients with pulmonary hypertension.

Authors:  Yuanyuan Sun; Lan Wang; Xiangrui Meng; Sugang Gong; Qinhua Zhao; Lingzi Shi; Rong Jiang; Jing He; Wenhui Wu; Yuan Li; Cijun Luo; Hongling Qiu; Jinling Li; Ping Yuan; Jinming Liu
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.